- Home
- ADCT vs UAC Comparison
ADCT vs UAC Comparison
Compare ADCT & UAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADCT | UAC |
|---|---|---|
| Founded | 2011 | 2025 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.1M | 137.6M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ADCT | UAC |
|---|---|---|
| Price | $1.47 | $10.00 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 59.0K |
| Earning Date | 11-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $0.78 | $9.51 |
| 52 Week High | $4.98 | $10.01 |
Technical Indicators
Market Signals| Indicator | ADCT | UAC |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 62.23 |
| Support Level | $0.97 | $9.51 |
| Resistance Level | $1.87 | N/A |
| Average True Range (ATR) | 0.18 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 40.30 | 83.33 |
Price Performance
Historical ComparisonAbout ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).